THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [10.20]-C128 ID: TIP-MED-000398

Sodium Zirconium Cyclosilicate

Active Ingredient / Scientific Identity: Sodium Zirconium Cyclosilicate • Class: Non-Calcium Polymeric Phosphate Binder & Gastrointestinal Potassium-Binding Resins for CKD (Schedule H)

⚖️ Compare Profile
Generic / Entity NameSodium Zirconium Cyclosilicate ([10.20]-C128)
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassNon-Calcium Polymeric Phosphate Binder & Gastrointestinal Potassium-Binding Resins for CKD
Available Dosage FormsSevelamer Carbonate Tablets: 400 mg, 800 mg; Oral Powder Sachet: 800 mg, 2.4 g. Calcium Polystyrene Sulfonate
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal: Non-absorbed polymers (<1% systemic absorption) — specifically designed for CKD Stage 4–5 and dialysis. Hepatic: Safe
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Sodium Zirconium Cyclosilicate (TIP-MED-000398, Reference Code [10.20]-C128) is classified under Vitamins, Minerals & Nutrition — CKD-MBD & Electrolyte Binders/Buffers (Ch 10) as a Non-Calcium Polymeric Phosphate Binder & Gastrointestinal Potassium-Binding Resins for CKD (Schedule H). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Co-indexed constituent under primary monograph [10.20] (Sevelamer Carbonate & Calcium Polystyrene Sulfonate / Sodium Zirconium Cyclosilicate). Representative Indian Market Examples (Edition 2.7 Ch 10 [10.20], p. 136): Sevelamer Carbonate: Renvela (Sanofi), Foseal (Emcure), Sevcar (Emcure), Acutrol-C. Calcium Polystyrene Sulfonate (CPS): K-Bind (Steadfast — 15 g Sachet), Kayexalate. Sodium Zirconium Cyclosilicate (SZC): Lokelma (AstraZeneca — 5 g / 10 g Sachet) — Strengths & Dosage Forms: Sevelamer Carbonate Tablets: 400 mg, 800 mg; Oral Powder Sachet: 800 mg, 2.4 g. Calcium Polystyrene Sulfonate (K-Bind) Sachet: 15 g. Sodium Zirconium Cyclosilicate Sachet: 5 g, 10 g
Co-indexed constituent under primary monograph [10.20] (Sevelamer Carbonate & Calcium Polystyrene Sulfonate / Sodium Zirconium Cyclosilicate). Representative Indian Market Examples (Edition 2.7 Ch 10 [10.20], p. 136): Sevelamer Carbonate: Renvela (Sanofi), Foseal (Emcure), Sevcar (Emcure), Acutrol-C. Calcium Polystyrene Sulfonate (CPS): K-Bind (Steadfast — 15 g Sachet), Kayexalate. Sodium Zirconium Cyclosilicate (SZC): Lokelma (AstraZeneca — 5 g / 10 g Sachet) — Strengths & Dosage Forms: Sevelamer Carbonate Tablets: 400 mg, 800 mg; Oral Powder Sachet: 800 mg, 2.4 g. Calcium Polystyrene Sulfonate (K-Bind) Sachet: 15 g. Sodium Zirconium Cyclosilicate Sachet: 5 g, 10 g
Dosage Forms & Available Strengths:
Sevelamer Carbonate Tablets: 400 mg, 800 mg; Oral Powder Sachet: 800 mg, 2.4 g. Calcium Polystyrene Sulfonate (K-Bind) Sachet: 15 g. Sodium Zirconium Cyclosilicate Sachet: 5 g, 10 g
Routes: Oral / Parenteral / Topical per formulation

3. Mechanism of Action & Pharmacodynamics

Non-Calcium Polymeric Phosphate Binder & Gastrointestinal Potassium-Binding Resins for CKD (Schedule H) acting on target receptor/enzyme pathways in Vitamins, Minerals & Nutrition — CKD-MBD & Electrolyte Binders/Buffers (Ch 10): clinical efficacy is mediated via Non-Calcium Polymeric Phosphate Binder & Gastrointestinal Potassium-Binding Resins for CKD (Schedule H) for Sevelamer: Control of Hyperphosphataemia (Serum Phosphate >4.5–5.5 mg/dL) in CKD Stage 4–5 and dialysis (non-absorbed, calcium-free polymer that binds dietary phosphate in the gut without causing hypercalcaemia; also lowers LDL-C by 15–30%!). CPS (K-Bind) & SZC (Lokelma): Treatment of Hyperkalaemia (Serum K+ >5.0–5.5 mEq/L) in CKD or patients on RAASi.

4. Therapeutic Indications & Evidence-Supported Uses

  • Sevelamer: Control of Hyperphosphataemia (Serum Phosphate >4
  • 5 mg/dL) in CKD Stage 4–5 and dialysis (non-absorbed, calcium-free polymer that binds dietary phosphate in the gut without causing hypercalcaemia
  • also lowers LDL-C by 15–30%!)
  • CPS (K-Bind) & SZC (Lokelma): Treatment of Hyperkalaemia (Serum K+ >5
  • 5 mEq/L) in CKD or patients on RAASi

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Sevelamer Carbonate: Start 400–800 mg PO THREE TIMES DAILY WITH MEALS (titrate to 800–1600 mg TDS with meals to keep Serum Phosphate 3.5–5.5 mg/dL). K-Bind (CPS): 15 g sachet suspended in 60–100 mL water PO 1–3 times daily. SZC (Lokelma): Correction: 10 g TDS x 48h; Maintenance: 5–10 g OD

Administration & Meal Timing: OPPOSITE TIMING RULES: (1) Sevelamer (Foseal/Sevcar) MUST BE SWALLOWED WHOLE RIGHT WITH MEALS (taking Sevelamer on an empty stomach is 100% useless! Never crush or chew Sevelamer tablets as they swell in saliva and cause choking!). (2) Separate K-Bind and Lokelma by AT LEAST 2–3 HOURS from all other oral medications! | Sevelamer: WITH Breakfast, Lunch & Dinner. K-Bind / Lokelma: Separated >=2–3h from other drugs

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Follows class pharmacokinetic profile detailed in parent monograph [10.20].
Metabolism & Biotransformation:
Renal: Non-absorbed polymers (<1% systemic absorption) — specifically designed for CKD Stage 4–5 and dialysis. Hepatic: Safe
Elimination & Renal Adjustment:
Renal: Non-absorbed polymers (<1% systemic absorption) — specifically designed for CKD Stage 4–5 and dialysis. Hepatic: Safe
Hepatic Impairment Considerations:
Renal: Non-absorbed polymers (<1% systemic absorption) — specifically designed for CKD Stage 4–5 and dialysis. Hepatic: Safe

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Sevelamer CONTRAINDICATED in hypophosphataemia and bowel obstruction/ileus. K-Bind (CPS) CONTRAINDICATED in Serum K+ <5.0 mEq/L, obstructive bowel disease, postoperative ileus, and severe constipation — NEVER mix SPS/CPS with Sorbitol (causes fatal colonic necrosis and intestinal perforation!)!

Key Clinical Precautions: Renal: Non-absorbed polymers (<1% systemic absorption) — specifically designed for CKD Stage 4–5 and dialysis. Hepatic: Safe

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Sevelamer: Constipation, nausea, dyspepsia, flatulence. K-Bind: Constipation, faecal impaction, nausea, hypokalaemia, hypercalcaemia. Lokelma: Mild ankle oedema
  • Sevelamer: Bowel obstruction/perforation, oesophageal obstruction if dry-swallowed or chewed; K-Bind/SPS: Fatal Colonic Necrosis / Intestinal Perforation (especially if constipated!), severe hypokalaemia
Serious / Dose-Limiting Adverse Effects:

    9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

    • BROAD GI DRUG BINDING: Both Sevelamer and Potassium-binding resins bind oral medications in the gut — separate Ciprofloxacin, Levofloxacin, Levothyroxine (space >=4h!), Mycophenolate (MMF), Tacrolimus, Cyclosporine, Dabigatran, Digoxin, and Lithium by AT LEAST 2–3 HOURS before or after Sevelamer or K-Bind/Lokelma!

    10. Clinical Monitoring, Patient Counselling & Storage

    Clinical & Laboratory Monitoring: Monitor clinical parameters per parent monograph [10.20].

    Pharmacist Patient Counselling Points:

    • Patient Counselling Checklist: FOUR VITAL CKD COUNTER RULES: (1) Take Foseal/Sevcar (Sevelamer) right WITH your meals and swallow the large tablet whole with water (never chew it, and skip it if you skip a meal); (2) Mix K-Bind sachet in plain water (NEVER fruit juice/coconut water!) and report constipation immediately; (3) Space Thyroid tablets (Thyronorm), Ciprofloxacin, or transplant drugs at least 3–4 hours away from Sevelamer and K-Bind
    • Meal & Clock Timing Instruction: OPPOSITE TIMING RULES: (1) Sevelamer (Foseal/Sevcar) MUST BE SWALLOWED WHOLE RIGHT WITH MEALS (taking Sevelamer on an empty stomach is 100% useless! Never crush or chew Sevelamer tablets as they swell in saliva and cause choking!). (2) Separate K-Bind and Lokelma by AT LEAST 2–3 HOURS from all other oral medications! (Sevelamer: WITH Breakfast, Lunch & Dinner. K-Bind / Lokelma: Separated >=2–3h from other drugs)
    • Missed Dose Protocol: Sevelamer: If forgotten during a meal, skip it (never take between meals!). K-Bind: Check K+ before repeating
    • Geriatric Dispensing Pearl: Ensure older CKD patients have regular bowel movements before giving K-Bind (CPS) to prevent faecal impaction and colonic necrosis

    Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Sevelamer Carbonate Tablets: 400 mg, 800 mg; Oral Powder Sachet: 800 mg, 2.4 g. Calcium Polystyrene Sulfonate (K-Bind) Sachet: 15 g. Sodium Zirconium Cyclosilicate Sachet: 5 g, 10 g

    11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

    THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
    svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

    12. Authoritative References, Regulatory Sources & Editorial Disclaimer

    Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO

    Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

    Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

    Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.